feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouUnited StatesUnited States
You
bookmarksYour BookmarkshashtagYour Topics
Trending
Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2026 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / New Therapy Turns Cancer's Allies Against It

New Therapy Turns Cancer's Allies Against It

11 Jan

•

Summary

  • New treatment reprograms macrophages within tumors.
  • CAR-macrophages are generated directly inside the body.
  • Animal studies show significant reduction in tumor growth.
New Therapy Turns Cancer's Allies Against It

A groundbreaking advancement in cancer immunotherapy has emerged from KAIST, offering a new way to combat solid tumors. Researchers have successfully developed a method to reprogram immune cells, specifically macrophages, directly inside the tumor environment. This innovative approach avoids the costly and time-consuming process of extracting and modifying cells in a lab.

The treatment utilizes lipid nanoparticles containing mRNA instructions and immune-activating compounds. When injected into a tumor, these nanoparticles are absorbed by macrophages, transforming them into "CAR-macrophages." These reprogrammed cells are now capable of recognizing and attacking cancer cells, and they also stimulate other immune cells, amplifying the body's defense.

Initial studies in animal models, particularly for melanoma, have shown remarkable results, with significant suppression of tumor growth. This new strategy not only addresses the challenges of delivering therapies to solid tumors but also overcomes the immunosuppressive nature of the tumor microenvironment, presenting a powerful new tool against cancer.

trending

Roblox CEO sells stock

trending

Tigers linked to Bassitt, Giolito

trending

Wawrinka gets Australian Open wildcard

trending

Ozark Trail stoves recalled

trending

Switzerland reaches United Cup final

trending

Hurkacz leads Poland to title

trending

Medvedev credits Aussie coach revival

trending

Adithya Ashok: New Zealand Squad

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
KAIST's new approach reprograms macrophages already present inside tumors into cancer-fighting CAR-macrophages directly within the body.
It bypasses the need to extract and modify cells externally, instead converting existing macrophages within the immunosuppressive tumor environment.
Animal studies showed significant reduction in tumor growth and a potent anticancer immune response.

Read more news on

Healthside-arrow

You may also like

Beyond Lifestyle: Unveiling Genetic Cancer

9 Jan • 15 reads

article image

Advanced Tongue Cancer Defeated: Reconstruction Success

7 Jan • 32 reads

article image

Cancer Treatment Timing Matters: Early Doses Boost Survival

23 Dec, 2025 • 88 reads

article image

Desmoid Tumor Drug Shows Promise

16 Dec, 2025 • 129 reads

article image

Earlier Cancer Doses Linked to Longer Survival

9 Dec, 2025 • 150 reads